Taletrectinib in ROS1 mutated Non–Small Cell Lung Cancer
1 .The objective response rate was 88.8% for TKI-naïve patients and 55.8% for TKI-pretreated patients. 2. Most common adverse events ...
1 .The objective response rate was 88.8% for TKI-naïve patients and 55.8% for TKI-pretreated patients. 2. Most common adverse events ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.